A Pascher1, J Klupp, J M Langrehr, P Neuhaus. 1. Department of General and Transplantation Surgery, Charité, Campus Virchow Clinic, Berlin, Germany. andreas.pascher@charite.de
Abstract
INTRODUCTION: We present our experience with infliximab rescue therapy for steroid- and OKT3-resistant rejection after intestinal transplantation (ITx). METHODS: Twelve ITx and one multivisceral transplant recipients were immunosuppressed with tacrolimus, rapamycin, daclizumab, steroids (n = 10) or tacrolimus, campath, and steroids (n = 3). RESULTS: In two patients, severe acute rejection did not resolve despite steroid bolus therapy plus 5 to 10 days of OKT3 treatment. Signs of moderate rejection persisted in the distal portions of the grafts. Treatment with infliximab, a chimeric anti-TNF-alpha antibody (four infusions of 3 mg/kg body weight), induced a complete remission of histological and clinical signs of rejection. Two further patients with steroid-resistant rejection received two courses of infliximab (3 mg/kg body weight) as antirejection therapy. All rejection episodes resolved completely. CONCLUSIONS: Infliximab effectively treats steroid and OKT3 resistant acute rejection episodes of intestinal transplantations.
INTRODUCTION: We present our experience with infliximab rescue therapy for steroid- and OKT3-resistant rejection after intestinal transplantation (ITx). METHODS: Twelve ITx and one multivisceral transplant recipients were immunosuppressed with tacrolimus, rapamycin, daclizumab, steroids (n = 10) or tacrolimus, campath, and steroids (n = 3). RESULTS: In two patients, severe acute rejection did not resolve despite steroid bolus therapy plus 5 to 10 days of OKT3 treatment. Signs of moderate rejection persisted in the distal portions of the grafts. Treatment with infliximab, a chimeric anti-TNF-alpha antibody (four infusions of 3 mg/kg body weight), induced a complete remission of histological and clinical signs of rejection. Two further patients with steroid-resistant rejection received two courses of infliximab (3 mg/kg body weight) as antirejection therapy. All rejection episodes resolved completely. CONCLUSIONS:Infliximab effectively treats steroid and OKT3 resistant acute rejection episodes of intestinal transplantations.
Authors: T Pech; J Fujishiro; T Finger; I Ohsawa; M Praktiknjo; M von Websky; S Wehner; K Abu-Elmagd; J C Kalff; N Schaefer Journal: Langenbecks Arch Surg Date: 2011-09-30 Impact factor: 3.445
Authors: Jason M Zimmerer; Phillip H Horne; Lori A Fiessinger; Mason G Fisher; Thomas A Pham; Samiya L Saklayen; Ginny L Bumgardner Journal: Transplantation Date: 2012-12-15 Impact factor: 4.939
Authors: Ahmet Fikret Yucel; Ahmet Pergel; Ibrahim Aydin; Hasan Alacam; Ilhan Karabicak; Tugrul Kesicioglu; Levent Tumkaya; Yildiray Kalkan; Ender Ozer; Zakir Arslan; Ibrahim Sehitoglu; Dursun Ali Sahin Journal: Int J Clin Exp Med Date: 2015-11-15